atezolizumab + entinostat

Atezolizumab + entinostat is an investigational combination therapy consisting of two agents: atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and entinostat, an oral small molecule inhibitor of class I histone deacetylases (HDACs). Atezolizumab acts as an immune checkpoint inhibitor by blocking PD-L1, thereby enhancing T-cell mediated anti-tumor immunity. Entinostat modulates the tumor microenvironment by inhibiting HDACs, which can suppress regulatory T cell function and myeloid-derived suppressor cells, potentially increasing the efficacy of immunotherapies like PD-L1 inhibitors. The combination has been studied in several cancer types including advanced triple-negative breast cancer (aTNBC), renal cell carcinoma, and extensive-stage small cell lung cancer. Clinical trials have shown that while the combination may enhance immune response in some settings, it has also resulted in increased toxicity without clear improvement in efficacy over monotherapy or standard regimens[6][7][2].

Brand names

Tecentriq (for atezolizumab)